期刊文献+

不同ARB类药物对CHD患者的抗炎、调脂水平的差异性探究 被引量:2

Study on the difference of anti-inflammatory and lipid regulating of different ARB drugs in CHD patients
下载PDF
导出
摘要 目的:探讨临床上常用ARB类药物对冠心病(Coronary heart disease,CHD)患者的抗炎及调脂水平差异。方法:入选确诊冠心病(CHD)患者135例,随机分为缬沙坦组、厄贝沙坦组及替米沙坦组,观察各组治疗前及治疗1个月后的血浆Cox-2、TNF-a及胆固醇(TC)及甘油三酯(TG)水平。结果:缬沙坦及替米沙坦组治疗前后的炎症因子Cox-2、TNF-a水平表达具有统计学差异(P<0.05)。厄贝沙坦组治疗前后的炎症因子Cox-2水平表达具有统计学差异(P<0.05),但TNF-a水平表达无统计学差异。缬沙坦组治疗前后的TC、TG水平表达具有统计学差异(P<0.05)。厄贝沙坦组及替米沙坦组治疗前后的TC水平表达具有统计学差异(P<0.05),但TG水平无统计学差异。结论:缬沙坦、厄贝沙坦及替米沙坦均在一定程度上具有减少炎症因子释放,降低血脂(包括TC、TG)水平的作用,但各具特点。 Objective:To investigate the anti-inflammatory and lipid regulating effects of Angiotensin Receptor Blocker(ARB)drugs commonly used in clinical practice on coronary heart disease.Methods:A total of 135 patients with coronary heart disease(CHD)were randomly divided into valsartan group,irbesartan group and telmisartan group.The levels of plasma Cox-2,TNF-a,cholesterol and triglyceride were observed before treatment and one months after treatment.Results:There were significant differences in the levels of inflammatory factors Cox-2 and TNF-a before and after treatment in valsartan and telmisartan groups(P<0.05).There was significant difference in the level of inflammatory factor Cox-2 before and after treatment in irbesartan group(P<0.05),but there was no significant difference in the expression of TNF-a.The expression of TC and TG in valsartan group before and after treatment had statistical difference(P<0.05).There was significant difference in the level of TC between irbesartan group and telmisartan group before and after treatment(P<0.05),but there was no significant difference in TG level between the two groups.Conclusion:Valsartan,irbesartan and telmisartan can reduce the release of inflammatory factors and decrease the levels of lipids(including TC and TG)to some extent,but each has its own characteristics.
作者 何东 黄春艳 HE Dong;HUANG Chunyan(Department of Cardiology,The People's Hospital of Deyang City,Deyang 618000,China;Department of Geriatrics,The Integrated Medicine Hospital,Sichuan,Chendu 610000,China)
出处 《包头医学院学报》 CAS 2019年第1期49-50,共2页 Journal of Baotou Medical College
关键词 缬沙坦 厄贝沙坦 替米沙坦 动脉粥样硬化 Stan Irbesartan Telmisartan Atherosclerosis
  • 相关文献

参考文献6

二级参考文献69

  • 1张丹凤,夏向南.心脑血管病患者血液流变学变化[J].福建医科大学学报,2005,39(2):210-212. 被引量:7
  • 2季闽春,沈晓英,杨耀芳.心血管病治疗中抗血小板聚集药物抵抗的研究进展[J].中国药房,2006,17(13):1024-1026. 被引量:3
  • 3SOLYMOSS B C,BOURASSA M G,CAMPEAU L A,et al.Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity[J].Am J Cardiol,2004,93(2):159.
  • 4Ridker P M.High-sensitivity C-reactive protein:potenfial adjunct for global risk assessment in the ptimmy prevention of cardiovascular disease[J].Circulation,2001,103(13):1813.
  • 5Koenig W,Lowd lq,Baumert J,et al.C-reactive protein modulates risk prediction based on the Framinghm score:implications for future risk assessment:results from a Iarge cohort study in southern Germany[J].Circuhfion,2004,109(10):1349.
  • 6Barath P,Fishbein CM,Cao J,eI a1.Detection and localization 0f TNF in human atheroma[J].Am J Cardiol,1990,65(4):297.
  • 7Mallat Z,Corbaz A,Seoazee A,et al.Interleukin-18 /Interleukin-18 binding protein signaling modulates atheroselerotic lesion development and stability[J].Circ Res,2001,89:41.
  • 8Gragie J,Robertson S.IL-18[J].J Leukoe Biol,2003,7(3):213.
  • 9Danesh J,Wheeler JG,Hirschfield GM,et al.C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease[J].N Engl J Med,2004,350(14):1387.
  • 10王永炎.关于提高脑血管疾病疗效难点的思考[J].中国中西医结合杂志,1997,17(4):195-196. 被引量:604

共引文献69

同被引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部